Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.97% | 21.54% | 89.46% | 75.20% | 76.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.97% | 21.54% | 89.46% | 75.20% | 76.23% |
| Cost of Revenue | 4.18% | 11.09% | 31.04% | 70.96% | 83.87% |
| Gross Profit | 26.81% | 23.52% | 102.99% | 76.04% | 74.75% |
| SG&A Expenses | 22.61% | 8.72% | 1.41% | 2.87% | 3.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.91% | 9.86% | 8.63% | 12.82% | 15.80% |
| Operating Income | 37.31% | 46.91% | 112.42% | 77.69% | 64.06% |
| Income Before Tax | 12.95% | 36.14% | 94.18% | 69.36% | 61.53% |
| Income Tax Expenses | -1,575.36% | 59.11% | 180.81% | 49.16% | 61.54% |
| Earnings from Continuing Operations | 36.82% | 34.83% | 93.14% | 68.82% | 61.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.82% | 34.83% | 93.14% | 68.82% | 61.08% |
| EBIT | 37.31% | 46.91% | 112.42% | 77.69% | 64.06% |
| EBITDA | 47.30% | 55.88% | 120.41% | 83.45% | 69.20% |
| EPS Basic | 38.54% | 36.38% | 93.35% | 69.50% | 61.98% |
| Normalized Basic EPS | 12.84% | 36.72% | 95.65% | 69.00% | 59.98% |
| EPS Diluted | 38.96% | 36.88% | 93.03% | 69.20% | 61.73% |
| Normalized Diluted EPS | 14.43% | 37.70% | 94.86% | 68.22% | 59.23% |
| Average Basic Shares Outstanding | 2.20% | 1.97% | 1.92% | 2.28% | 2.65% |
| Average Diluted Shares Outstanding | 0.96% | 0.74% | 3.16% | 3.53% | 3.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |